News
12-16-2013, 12:44 AM
The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
More... (http://www.news-medical.net/news/20131216/Adding-drug-to-presurgery-chemotherapy-improves-results-for-women-with-triple-negative-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20131216/Adding-drug-to-presurgery-chemotherapy-improves-results-for-women-with-triple-negative-breast-cancer.aspx)